Pancreatic Cancer Research

ResearcherFred Hutch Cancer CenterActive in the last 2 years

Venu Gopal Pillarisetty

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-1162-9643; OpenAlex author ID A5025523782; NIH RePORTER profile ID 11414307. Sources: OpenAlex.

Their work

Papers
19 (first author 2, last author 5)
Trials
0
Grants
1
Labs led
1
Collaborators
48
Papers, trials and grants by year

2014: 3 papers · 2015: none · 2016: 1 paper · 2017: 4 papers · 2018: none · 2019: 3 papers · 2020: none · 2021: 1 paper · 2022: 1 paper · 2023: 1 paper · 2024: 2 papers · 2025: 2 papers · 2026: 1 paper, 1 grant

Papers 19

  1. Neoadjuvant therapy-induced remodeling of tumor immune microenvironment in pancreatic ductal adenocarcinoma: a spatial and digital pathology analysis. Co-author DOI 10.1007/s00428-025-04056-y↗
  2. Long-Term Survival Following Chemoradiation in Locoregional Recurrent Germline ATM Mutated Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.adro.2025.101742↗
  3. Complement activation in tumor microenvironment after neoadjuvant therapy and its impact on pancreatic cancer outcomes. Co-author DOI 10.1038/s41698-025-00848-2↗
  4. Evaluating surgeon communication of pancreatic cancer prognosis using the VitalTalk ADAPT framework. Co-author DOI 10.1002/jso.27777↗
  5. Intratumoral T-cell receptor repertoire composition predicts overall survival in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1080/2162402x.2024.2320411↗
  6. Perioperative Chemotherapy and Chemoradiotherapy for Patients With Resectable and Borderline Resectable Pancreatic Adenocarcinoma. First author DOI 10.1097/mpa.0000000000002253↗
  7. Combination immunotherapy for pancreatic cancer: challenges and future considerations. Co-author DOI 10.1080/1744666x.2022.2120471↗
  8. DNA Damage Repair Defects and Survival Outcomes for Patients With Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000001819↗
  9. Screening for Pancreatic Cancer: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. Co-author DOI 10.1001/jama.2019.6190↗
  10. Mobilization of CD8+ T Cells via CXCR4 Blockade Facilitates PD-1 Checkpoint Therapy in Human Pancreatic Cancer. Last author DOI 10.1158/1078-0432.ccr-19-0081↗
  11. Hypoxia as a barrier to immunotherapy in pancreatic adenocarcinoma. Last author DOI 10.1186/s40169-019-0226-9↗
  12. T-cell programming in pancreatic adenocarcinoma: a review. First author DOI 10.1038/cgt.2016.66↗
  13. Disrupting glutamine metabolic pathways to sensitize gemcitabine-resistant pancreatic cancer. Co-author DOI 10.1038/s41598-017-08436-6↗
  14. Focused ultrasound for immuno-adjuvant treatment of pancreatic cancer: An emerging clinical paradigm in the era of personalized oncotherapy. Co-author DOI 10.1080/08830185.2017.1363199↗
  15. Long-lived pancreatic ductal adenocarcinoma slice cultures enable precise study of the immune microenvironment. Last author DOI 10.1080/2162402x.2017.1333210↗
  16. Role of immune cells in pancreatic cancer from bench to clinical application: An updated review. Last author DOI 10.1097/md.0000000000005541↗
  17. Pancreatic ductal adenocarcinoma contains an effector and regulatory immune cell infiltrate that is altered by multimodal neoadjuvant treatment. Last author DOI 10.1371/journal.pone.0096565↗
  18. FOXP3+ lymphocyte density in pancreatic cancer correlates with lymph node metastasis. Co-author DOI 10.1371/journal.pone.0106741↗
  19. The pancreatic cancer microenvironment: an immunologic battleground. Co-author DOI 10.4161/21624011.2014.950171↗

Grants 1

  1. Ex vivo drug testing with patient derived tumor cells for translational research. R56CA309037↗

Closest collaborators

The 25 strongest of 48 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Christopher J Kemp · 1 shared grant, 2026 · strength 1.26
  2. Elena Gabriela Chiorean · 4 shared papers, 2021–2025 · strength 0.74
  3. Jonathan G. Sham · 4 shared papers, 2014–2025 · strength 0.65
  4. Danting Li · 2 shared papers, 2025–2026 · strength 0.56
  5. Yaozhong Liu · 2 shared papers, 2025–2026 · strength 0.56
  6. David Bing Zhen · 3 shared papers, 2021–2023 · strength 0.51
  7. Yongwoo David Seo · 4 shared papers, 2017–2024 · strength 0.49
  8. Andrew L. Coveler · 3 shared papers, 2017–2023 · strength 0.35
  9. Sita Kugel · 1 shared paper, 2025 · strength 0.24
  10. Rachael Ann Safyan · 1 shared paper, 2025 · strength 0.24
  11. Dushyant V. Sahani · 1 shared paper, 2025 · strength 0.24
  12. Gustavo Cartaxo de Lima Gössling · 1 shared paper, 2022 · strength 0.22
  13. Lindsay K. Dickerson · 1 shared paper, 2024 · strength 0.22
  14. Kevin M. Sullivan · 2 shared papers, 2019 · strength 0.22
  15. Sara K. Daniel · 2 shared papers, 2019 · strength 0.22
  16. Xiaofei Zhang · 1 shared paper, 2025 · strength 0.21
  17. Michael Shusterman · 1 shared paper, 2025 · strength 0.21
  18. Jessica L. Widmer · 1 shared paper, 2025 · strength 0.21
  19. John Allendorf · 1 shared paper, 2025 · strength 0.21
  20. Graham D. Hogg · 1 shared paper, 2024 · strength 0.20
  21. William G. Hawkins · 1 shared paper, 2024 · strength 0.20
  22. Vikram S. Pothuri · 1 shared paper, 2024 · strength 0.20
  23. C. Alston James · 1 shared paper, 2024 · strength 0.20
  24. Ryan C Fields · 1 shared paper, 2024 · strength 0.20
  25. David G DeNardo · 1 shared paper, 2024 · strength 0.20

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.